The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500 - 1/1000. Detects a band of approximately 27 kDa (predicted molecular weight: 27 kDa).
Involved in muscle differentiation (myogenic factor). Induces fibroblasts to differentiate into myoblasts. Probable sequence specific DNA-binding protein.
Defects in MYF6 may be a cause of centronuclear myopathy autosomal dominant (ADCNM) [MIM:160150]; also known as autosomal dominant myotubular myopathy. Centronuclear myopathies are congenital muscle disorders characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.
All lanes : Anti-MYF6 antibody (ab64802) at 1/500 dilution
Lane 1 : Extracts from 293 cells at 5-30ug with no immunizing peptide Lane 2 : Extracts from HepG2 cells at 5-30ug with no immunizing peptide Lane 3 : Extracts from HepG2 cells at 5-30ug with immunizing peptide at 5-10ug
Predicted band size : 27 kDa Observed band size : 27 kDa